Results 151 to 160 of about 26,068 (276)
Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
Integrated Blood Pressure Control, 2013 Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone was shown to be an extraordinarily effective ...
openaire +4 more sources
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims The American Diabetes Association recommends achieving treatment goals (glycated haemoglobin ≤ 53 mmol/mol [7.0%], blood pressure < 130/80 mmHg, low‐density lipoprotein cholesterol < 1.81 mmol/L and use of sodium–glucose cotransporter‐2 inhibitors or glucagon‐like peptide‐1 receptor agonists), to reduce cardiovascular and kidney ...
João Sérgio Neves +12 more
wiley +1 more source
Hyperaldosteronism in the Pathophysiology and Management of Cardiovascular‐Kidney‐Metabolic Syndrome
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Cardiovascular‐kidney‐metabolic (CKM) syndrome is defined by the pathologic interconnections between obesity, diabetes, chronic kidney disease and cardiovascular disease. An important and underrecognized pathophysiologic factor underlying CKM syndrome is obesity‐induced aldosterone excess.
Evan Zeitler +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims In a phase 2 trial, the efficacy and safety of the highly selective aldosterone synthase inhibitor vicadrostat, alone or with empagliflozin, were investigated in people with chronic kidney disease (CKD) with or without type 2 diabetes (T2D). Materials and Methods Adults (n = 586) with CKD (estimated glomerular filtration rate [eGFR] 30 to
David Z. I. Cherney +14 more
wiley +1 more source
Терапевтический архив, 2015 Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials.
Yu F Osmolovskaya +2 more
doaj
Intramyocardial gene silencing by interfering RNA [PDF]
, 2017 RNAi is a widely used methodology for gene silencing. The action mechanism of siRNA molecules has been well studiedin recent years, and the technique has been optimized in terms of safety and effectiveness. Cardiovascular diseases havea high incidence in
Brea, María Soledad +2 more
core +1 more source
Hepatology Research, EarlyView.Mineralocorticoid receptor antagonists are known to reduce proteinuria in chronic kidney disease, but their effectiveness in preventing bevacizumab‐related proteinuria has not been well established. In the present multi‐institutional retrospective study, we found that these agents significantly delay the onset of moderate or higher grade proteinuria ...
Tomoki Hori +17 more
wiley +1 more source
Internal Medicine Journal, EarlyView.Abstract Background Chronic kidney disease (CKD) is a significant public health challenge in Australia, affecting ~10% of the adult population and contributing to substantial morbidity and mortality. Diabetes, hypertension, cardiovascular disease and CKD frequently co‐exist; therefore, a multidisciplinary approach is necessary to manage these ...
M. P. Schlaich +7 more
wiley +1 more source
Journal of Diabetes Investigation, EarlyView.SGLT2 inhibitor use at discharge was associated with a reduced risk of heart failure readmission in elderly patients with diabetes, with no significant differences among individual agents. ABSTRACT Aims To evaluate the effect of sodium–glucose cotransporter 2 inhibitor (SGLT2i) administration at hospital discharge on heart failure (HF) readmission ...
Kazuya Hiura +3 more
wiley +1 more source